Drug Approval | October 23, 2023
Zhimeng Biopharma CB03 receives Orphan Drug Designation from the USFDA
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
Aarti Drugs has reported total income of Rs. 642.22 crores during the period ended September 30, 2023
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
Venus Remedies' oncology wing has also secured marketing authorisation from Myanmar for another chemotherapy drug
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
NRT offers 50% higher success rate in quitting smoking compared to unassisted attempts
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
The VitalDose Drug Delivery Platform has been used in patient-centric dose forms in women’s health for over two decades
In 2030 over 50% of FDA approvals will involve AI discovered and developed drugs
Subscribe To Our Newsletter & Stay Updated
